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Background/aim: Thiol-disulfide homeostasis is an important antioxidant defense mechanism. This study was conducted to investigate
dynamic thiol-disulfide homeostasis in patients with hepatitis B virus-related chronic hepatitis and liver cirrhosis.
Materials and methods: Seventy-one treatment-naive patients with chronic hepatitis B (CHB), 50 patients with hepatitis B virusassociated liver cirrhosis, and 45 healthy controls were included in the study. Serum total and native thiol concentrations and serum
disulfide concentrations were measured using an automated method.
Results: Mean serum total thiol concentrations in the control, CHB, and cirrhosis groups were 481.64 ± 37.87 µmol/L, 438.50 ± 71.35
µmol/L, and 358.07 ± 80.47 µmol/L, respectively (P < 0.001), and mean serum native thiol concentrations in the control, CHB, and
cirrhosis groups were 452.92 ± 36.43 µmol/L, 400.16 ± 65.92 µmol/L, and 328.15 ± 74.91 µmol/L, respectively (P < 0.001). Mean serum
disulfide concentrations in the control, CHB, and cirrhosis groups were 14.38 ± 3.38 µmol/L, 19.19 ± 6.16 µmol/L, and 14.98 ± 5.53
µmol/L, respectively (P < 0.001). There was a progressive decrease in both mean serum native and total thiol concentrations parallel to
the liver fibrosis stage.
Conclusion: : Thiol-disulfide homeostasis is disturbed in patients with hepatitis B virus-related chronic hepatitis and liver cirrhosis.
Key words: Hepatitis B, thiols, disulfides, oxidative stress

1. Introduction
Hepatitis B is an important healthcare problem. It is
estimated that global prevalence of hepatitis B is around
3.6% (1). Hepatitis B virus (HBV) causes a wide spectrum
of liver diseases ranging from inactive chronic carrier
state to end-stage liver disease and it is one of the most
important causes of hepatocellular carcinoma (HCC)
worldwide. The pathogenesis of chronic hepatitis B is
complex. Rather than the cytopathic effect of HBV itself,
hosts’ immune responses are shown to play key roles in
viral persistence and hepatocellular necroinflammation.
Several complex interactions involving viral factors,
hepatocytes, nonparenchymal liver cells, and inflammatory
cells have been described during the course of HBV-related
liver diseases (2). Several cytokines have also been shown
to be important in the pathogenesis of viral persistence,
hepatocellular inflammation, and fibrosis (3–5). There are

also a number of studies in the literature reporting that
oxidative stress may also contribute to the pathogenesis
of hepatocellular damage associated with HBV-related
chronic liver diseases (6–8). Oxidative stress has also been
implicated in the pathogenesis of HCC (9,10).
The human body is continuously exposed to oxidative
stress due to various reasons; therefore, it is essential
for the body to maintain effective antioxidant defense
mechanisms. Thiols are a group of compounds that
contain sulfhydryl groups in their structures. They are
one of the most important defense mechanisms against
oxidative stress. Oxidative stress leads to the formation
of reversible disulfide bonds between protein thiols and
other low-molecular-weight thiols, particularly with
glutathione. This process, so-called S-thiolation, has
regulatory effects on protein function (redox regulation)
while simultaneously protecting it from higher states
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of irreversible oxidation. Due to the reversible nature of
S-thiolation, reduced protein thiols can be regenerated
from their S-glutathionylated forms using various enzymes
such as disulfide isomerase, mitochondrial glutaredoxin,
or thioredoxin. These reactions maintain the dynamic
thiol-disulfide homeostasis and it is strictly controlled in
vitro. Besides being important for antioxidant defense,
thiol-disulfide homeostasis has also been shown to be
important for redox regulation of cell signaling and
apoptosis (11,12). Recently, Erel and Neselioglu developed
a novel, simple, and automated method to measure serum
total thiol, native thiol, and disulfide concentrations
allowing accurate determination of serum dynamic thioldisulfide homeostasis (13). Using this novel method,
disturbances in dynamic thiol-disulfide homeostasis were
shown in several diseases (14–17). As previously stated,
oxidative stress has also been implicated to contribute to
the pathogenesis of HBV-related chronic liver diseases and
HCC. In this context, the current study was conducted to
investigate dynamic thiol-disulfide homeostasis in patients
with HBV-associated chronic liver diseases.
2. Materials and methods
Seventy-one treatment-naive patients with chronic
hepatitis B (CHB), 50 patients with HBV-associated liver
cirrhosis, and 45 healthy controls were included in the
study. The study protocol was approved by the local ethics
committee of the Necmettin Erbakan University Faculty of
Medicine and written informed consent was received from
all the participants. The CHB group consisted of patients
who were positive for hepatitis B surface antigen (HBsAg)
for at least 6 months with active viral replication (HBV
DNA > 2000 IU/mL). Liver biopsy was performed for every
subject in the CHB group and the Ishak scoring system was
used for grading necroinflammation and fibrosis (18). The
cirrhosis group, on the other hand, consisted of HBsAgpositive patients for whom cirrhosis was diagnosed either
by liver biopsy (Ishak stage 5 and 6 fibrosis) or on the
basis of clinical, laboratory, and radiological findings.
Finally, the control group consisted of 45 healthy people
with normal liver enzymes and negative serological tests
for hepatitis B and C (HBsAg, hepatitis B core antibody,
anti-HCV antibody). Exclusion criteria were as follows:
patients with chronic liver diseases of any other etiology,
patients with considerable alcohol consumption (>20 g/
day for men and >10 g/day for women), and patients
with known malignancies, chronic renal diseases,
autoimmune diseases, or any active ongoing infections.
Serum samples were obtained early in the morning after
overnight fasting. Serum samples in CHB and cirrhosis
groups were obtained prior to the initiation of antiviral
therapy. Serum aspartate aminotransferase (AST), alanine
aminotransferase (ALT), alkaline phosphatase (ALP),
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and gamma-glutamyltransferase (GGT) activities as well
as other biochemical parameters were measured using
standard autoanalyzers. Serum samples for thiol-disulfide
homeostasis analyses were obtained by centrifugation
for 5 min at 4 °C and 4000 rpm and were transferred to a
freezer to be stored at –80 °C. All samples were analyzed
later the same day. As previously mentioned, dynamic
thiol-disulfide homeostasis parameters were measured
using Erel and Neselioglu’s method as follows: first,
sodium borohydride is added to the serum sample to
reduce all dynamic disulfide bonds to functional thiols.
Then formaldehyde is added to the milieu in order to
remove the excess of unconsumed sodium borohydride.
The total thiol concentration is measured using modified
Ellman reagent. Native thiol concentration is subtracted
from the total thiol concentration and half of the obtained
difference gives the disulfide bond amount.
Statistical analyses of the study were done using SPSS
19.0 for Windows (IBM Corp., Armonk, NY, USA).
Continuous variables were expressed as mean ± standard
deviation. Continuous variables were tested for normal
distribution using the one-sample Kolmogorov–Smirnov
test. Comparisons for more than two groups were done
with one-way ANOVA (normally distributed parameters)
and the Kruskal–Wallis test (nonnormally distributed
parameters). Student’s t-test and the Mann–Whitney U
test were used to test the significance of the differences
between two groups for normally and nonnormally
distributed parameters, respectively. The significance of the
linear correlation between continuous variables was tested
using the Pearson correlation coefficient test. Receiver
operating characteristic (ROC) curves were obtained for
tested parameters to predict severe inflammation and
advanced fibrosis. Sensitivity, specificity, and positive and
negative predictive values were calculated for specified
cutoff values. Statistical significance for all analyses was
defined as P < 0.05.
3. Results
The study group consisted of 71 (42.8%) treatment-naive
CHB patients, 50 patients (30.1%) with HBV-associated
liver cirrhosis, and 40 (27.1%) healthy controls. Sex
distribution was found to be similar in the study groups
(P = 0.06). Mean age, on the other hand, was found to
be significantly higher in the cirrhosis group than in the
CHB and control groups (48.73 ± 7.37, 46.70 ± 13.64, and
57.88 ± 9.91 years for control, CHB, and cirrhosis groups
respectively; P < 0.001). All patients in the CHB group
were positive for anti-HBe antibody. Demographical
characteristics and laboratory findings of the study groups
are summarized in Table 1.
Mean serum total thiol concentrations in the control,
CHB, and cirrhosis groups were 481.64 ± 37.87 µmol/L,
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Table 1. Clinical, demographical, and laboratory data and dynamic thiol-disulfide homeostasis parameters in the study groups.
Control group (n = 45)

Chronic hepatitis B (n = 71)

Cirrhosis (n = 50)

P

Age (years)

48.73 ± 7.37 a

46.70 ± 13.64 a

57.88 ± 9.91 b

<0.001

Male (n, %) / female (n, %)

23 (51.1) / 22 (48.9)

38 (53.5) / 33 (46.5)

36 (72) / 14 (28)

0.064

Creatinine (mg/dL)

0.76 ± 0.13

0.75 ± 0.12

0.77 ± 0.24

0.997

ALT (U/L)

20.87 ± 8.8 a

45.16 ± 43.01 b

36.49 ± 30.97 b

0.002

AST (U/L)

17.30 ± 7.75 a

33.67 ± 23.86 b

48.34 ± 41.40 c

<0.001

GGT (U/L)

19.53 ± 10.75 a

31.44 ± 27.11 b

74.50 ± 85.83 c

<0.001

ALP (U/L)

65.04 ± 13.68 a

83.79 ± 29.13 b

111.73 ± 54.33 c

<0.001

T.Bil (mg/dL)

0.73 ± 0.35 a

0.96 ± 0.58 b

2.84 ± 4.14 c

<0.001

D.Bil (mg/dL)

0.24 ± 0.13 a

0.45 ± 1.24 a

1.41 ± 2.51 b

0.004

Albumin (g/dL)

4.43 ± 0.25 a

4.31 ± 0.36 a

3.34 ± 0.66 b

<0.001

Hemoglobin (g/dL)

14.36 ± 1.67 a

15.14 ± 7.5 a

11.64 ± 2.57 b

0.001

Leukocytes (mm3)

6.92 ± 1.48 a

7.05 ± 1.83 a

5.11 ± 2.32 b

<0.001

Thrombocytes (mm )

252.58 ± 50.84 a

258.71 ± 150.74 a

105.22 ± 62.62 b

<0.001

Native thiol (µmol/L)

452.92 ± 36.43 a

400.16 ± 65.92 b

328.15 ± 74.91 c

<0.001

Total thiol (µmol/L)

481.64 ± 37.87 a

438.50 ± 71.35 b

358.07 ± 80.47 c

<0.001

Disulfide (µmol/L)

14.38 ± 3.38 a

19.19 ± 6.16 b

14.98 ± 5.53 a

<0.001

SS/SH%

3.18 ± 0.79 a

4.83 ± 1.44 b

4.64 ± 1.60 b

<0.001

SS/total thiol%

2.98 ± 0.69 a

4.38 ± 1.16 b

4.20 ± 1.32 b

<0.001

SH/total thiol%

94.03 ± 1.37 a

91.25 ± 2.33 b

91.58 ± 2.65 b

<0.001

3

ALT: Alanine aminotransferase, AST: aspartate aminotransferase, GGT: gamma-glutamyltransferase, ALP: alkaline phosphatase, T.Bil:
total bilirubin, D.Bil: direct bilirubin, SS: disulfide, SH: native thiol.
Letters a, b, and c denote binary comparisons between the groups. The difference between the groups is statistically significant if marked
with different letters.

438.50 ± 71.35 µmol/L, and 358.07 ± 80.47 µmol/L,
respectively, and the difference between the groups was
statistically significant (P < 0.001). Intergroup comparisons
showed that mean serum total thiol concentrations in
both the CHB (P < 0.001) and cirrhosis groups (P < 0.001)
were significantly lower than in the control group, and the
cirrhosis group also had significantly lower mean serum
total thiol concentration than the CHB group (P < 0.001).
Mean serum native thiol concentrations in the control,
CHB, and cirrhosis groups were 452.92 ± 36.43 µmol/L,
400.16 ± 65.92 µmol/L, and 328.15 ± 74.91 µmol/L,
respectively, and the difference between the groups
was also statistically significant (P < 0.001). Intergroup
comparisons showed that mean serum native thiol
concentrations in both the CHB (P < 0.001) and cirrhosis
groups (P < 0.001) were significantly lower than in healthy
controls and the cirrhosis group also had significantly
lower mean serum total thiol concentration than the CHB
group (P < 0.001).
Mean serum disulfide concentrations in the control,
CHB, and cirrhosis groups were 14.38 ± 3.38 µmol/L,

19.19 ± 6.16 µmol/L, and 14.98 ± 5.53 µmol/L, respectively,
and statistical analyses revealed that the CHB group had
significantly higher mean serum disulfide concentration
than both the control (P < 0.001) and cirrhosis groups
(P < 0.001), but the difference between the control and
cirrhosis groups was not statistically significant (P = 0.54).
Mean serum native thiol, total thiol, and disulfide
concentrations in the CHB, cirrhosis, and control groups
are summarized in Figure 1.
Mean native thiol/total thiol, disulfide/total thiol,
and disulfide/native thiol ratios in the control, CHB, and
cirrhosis groups are given in Table 1. Statistical analyses
showed that both disulfide/total thiol and disulfide/native
thiol ratios were significantly higher and native thiol/total
thiol ratio was significantly lower in the CHB and cirrhosis
groups when compared to healthy controls.
In order to search for the association of thiol-disulfide
homeostasis with the degree of liver fibrosis, patients in
the CHB group were divided into 2 subgroups according
to liver biopsy findings: mild fibrosis (Ishak stages 1 and 2)
and moderate fibrosis (Ishak stages 3 and 4). There were
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45 (63.4%) patients in the mild fibrosis and 26 (36.6%)
patients in the moderate fibrosis group. The cirrhosis
group was also included in the analyses as the advanced
fibrosis group. Findings are summarized in Table 2. As can
be seen, there was a significant progressive decrease in both
mean serum native thiol and total thiol concentrations in
parallel to the liver fibrosis stage and serum native thiol
and total thiol concentrations were lowest in patients
with advanced fibrosis (cirrhosis). Mean serum disulfide
concentration was also significantly different among mild,
moderate, and advanced fibrosis groups; both moderate
and advanced fibrosis groups had significantly lower mean
serum disulfide concentrations than the mild fibrosis
group. Mean serum disulfide concentration was also
lower in the advanced fibrosis group than in patients with

moderate fibrosis, but the difference was not statistically
significant (P = 0.11).
Liver biopsies were available for 73 patients (71 patients
in the CHB group and 2 patients in the cirrhosis group).
According to the degree of inflammation in liver biopsy
samples, patients were grouped into three categories: mild
inflammation (Ishak HAI: 1–8), moderate inflammation
(Ishak HAI: 9–18), and severe inflammation (Ishak HAI: 19–
24). There were 34 (46.6%) patients with mild inflammation,
23 (31.5%) patients with moderate inflammation, and 16
(21.9%) patients with severe inflammation. Mean serum
native thiol, total thiol, and disulfide concentrations were
found to be higher in the mild inflammation group when
compared to the moderate and severe inflammation groups.
Findings are summarized in Table 3.

Figure 1. Mean serum native thiol, total thiol, and disulfide concentrations in
chronic hepatitis B, cirrhosis, and control groups.
Table 2. Dynamic thiol-disulfide homeostasis parameters in patients with mild and moderate fibrosis and cirrhosis.
Chronic hepatitis B with mild
fibrosis (Ishak stage 1–2) (n = 45)

Chronic hepatitis B with moderate
fibrosis (Ishak stage 3–4) (n = 26)

Cirrhosis
(n = 50)

P

Native thiol (µmol/L)

414.08 ± 61.46 a

376.08 ± 67.58 b

328.15 ± 74.91 c

<0.001

Total thiol (µmol/L)

454.77 ± 65.67 a

410.37 ± 73.24 b

358.07 ± 80.47 c

<0.001

Disulfide (µmol/L)

20.37 ± 6.20 a

17.16 ± 5.64 b

14.98 ± 5.53 b

<0.001

SS/SH%

4.97 ± 1.45 a

4.60 ± 1.43 b

4.64 ± 1.60 b

0.493

SS/total thiol%

4.49 ± 1.14

4.18 ± 1.19

4.20 ± 1.32

0.450

SH/total thiol%

91.03 ± 2.29

91.63 ± 2.40

91.58 ± 2.65

0.474

SS: Disulfide, SH: native thiol.
Letters a, b, and c denote binary comparisons between the groups. The difference between the groups is statistically significant if marked
with different letters.
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There were 24 (48.0%) patients with compensated
and 26 patients (52.0%) with decompensated cirrhosis
in the cirrhosis group. Decompensation was defined as
the development of ascites, variceal bleeding, or hepatic
encephalopathy. Table 4 summarizes mean serum native
thiol, total thiol, and disulfide concentrations in the
compensated and decompensated patients. Mean serum
native thiol, total thiol, and disulfide concentrations
were found to be significantly lower in patients with
decompensated cirrhosis when compared to patients with
compensated cirrhosis.
Healthy controls were excluded from the analyses
and ROC curves were obtained for serum total thiol,
native thiol, and disulfide concentrations to differentiate
the advanced fibrosis group from patients with mild and
moderate fibrosis. For total thiol, the AUC was 0.779 (95%
CI: 0.695–0.864) and the specified cut-off value of 419.40
µmol/L yielded 78.0% sensitivity and 69.0% specificity. For
native thiol, the AUC was 0.768 (95% CI: 0.681–0.855)
and the specified cut-off value of 388.65 yielded 80.0%
sensitivity and 64.8% specificity. Lastly, for disulfide, the
AUC was 0.728 (95% CI: 0.634–0.822) and the specified

cut-off value of 16.30 yielded 72.0% sensitivity and 70.0%
specificity. ROC curves are summarized in Figure 2.
Regression analysis was performed to determine
independent factors affecting serum thiol-disulfide
parameters in patients with CHB and liver cirrhosis.
Fibrosis stage and age were found to be independently
associated with serum total and native thiol concentrations.
On the other hand, age was not an independent factor in
terms of serum disulfide concentration and only fibrosis
stage was identified as an independent factor affecting
serum disulfide concentration. Regression analyses are
summarized in Table 5.
4. Discussion
Free radicals, reactive oxygen, and nitrogen species are
continuously generated in the body as byproducts of
several physiological processes such as mitochondrial
oxidative phosphorylation, catabolism of lipids, amino
acids, or exogenous molecules such as drugs. These
substances are highly reactive and have hazardous effects
on several macromolecules within the cell, such as DNA,
proteins, and lipids, causing serious disturbances in

Table 3. Dynamic thiol-disulfide homeostasis parameters in patients with mild, moderate, and severe inflammation in liver biopsies.
Mild inflammation (n = 34)

Moderate inflammation (n = 23)

Severe inflammation (n = 16)

P

Native thiol (µmol/L)

424.91 ± 50.18 a

383.37 ± 71.62 b

354.98 ± 69.12 b

0.003

Total thiol (µmol/L)

467.01 ± 53.64 a

417.83 ± 75.94 b

389.62 ± 76.13 b

0.001

Disulfide (µmol/L)

21.07 ± 6.63 a

17.24 ± 4.44 b

17.34 ± 6.11 b

0.014

SS/SH%

4.99 ± 1.56

4.56 ± 1.17

4.91 ± 1.51

0.642

SS/total thiol%

4.51 ± 1.22

4.17 ± 0.99

4.44 ± 1.22

0.661

SH/total thiol%

90.99 ± 2.45

91.67 ± 1.99

91.23 ± 2.31

0.654

SS: Disulfide, SH: native thiol.
Letters a, b, and c denote binary comparisons between the groups. The difference between the groups is statistically significant if marked
with different letters.
Table 4. Dynamic thiol-disulfide homeostasis parameters in patients with compensated and
decompensated cirrhosis.
Compensated cirrhosis
(n = 24)

Decompensated cirrhosis
(n = 26)

P

Native thiol (µmol/L)

364.65 ± 63.74

294.46 ± 69.72

0.001

Total thiol (µmol/L)

397.46 ± 65.92

321.72 ± 76.37

0.001

Disulfide (µmol/L)

16.43 ± 4.41

13.64 ± 6.18

0.032

%SS/SH

4.60 ± 1.38

4.68 ± 1.81

0.847

%SS/total thiol

4.17 ± 1.13

4.24 ± 1.51

0.868

%SH/total thiol

91.63 ± 2.27

91.53 ± 3.01

0.885

SS: Disulfide, SH: native thiol.
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various cellular functions. Since the liver is the major
organ for several synthetic and detoxification reactions, it
is continuously exposed to oxidative stress. Therefore, the
oxidant/antioxidant balance is of particular importance
for the liver to function properly.
Oxidative stress has been implicated in the pathogenesis
of several chronic liver diseases, particularly fatty liver

disease and nonalcoholic steatohepatitis (17,19,20).
Oxidative stress has also been shown to contribute to the
pathogenesis of HBV-related chronic liver diseases. Severy
et al. (21) demonstrated that HBV replication induces
oxidative stress in the Hep AD 38 cell line in vivo and there
are several studies in the literature reporting that serum
and tissue markers of oxidative stress are increased in

Figure 2. ROC curves for serum total thiol, native thiol, and disulfide
concentrations to differentiate patients with advanced fibrosis from patients with
mild and moderate fibrosis.
Table 5. Regression analysis for independent factors affecting serum thiol-disulfide parameters in patients
with CHB and liver cirrhosis.

Fibrosis stage

Age

B

β

Total thiol

–54.78

Native thiol

–61.82

Disulfide
Total thiol

95% CI

P

Upper

Lower

–0.35

–82.13

–27.44

<0.001

–0.36

–91.25

–32.38

<0.001

–4.31

–0.34

–6.50

–2.13

<0.001

–1.57

–0.27

–2.58

–0.56

0.003

Native thiol

–1.71

–0.27

–2.8

–0.63

0.002

Disulfide

NA

NA

NA

NA

0.112

B: Regression coefficient, β: standardized correlation coefficient, CI: confidence interval, NA: not
applicable.
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patients with HBV-related chronic liver diseases. Valgimigli
et al. (22) reported that reactive oxygen species were
significantly increased in liver samples of CHB patients
when compared to healthy controls. In another study, serum
and erythrocyte levels of malondialdehyde (MDA), which is
a marker of lipid peroxidation, were shown to increase in
patients with CHB and correlate with serum ALT and HBV
DNA levels (23). MDA levels were also shown to correlate
with MELD scores in CHB patients with acute chronic liver
failure (24). Markers of protein and DNA oxidation were
also shown to increase in serum and hepatocytes of CHB
patients, which also supports the possible role of oxidative
stress in the pathogenesis of CHB (10,25). In addition to the
increase in markers of oxidative stress, there are studies in
the literature reporting decreases in antioxidant markers in
patients with HBV-associated chronic liver diseases (23,26).
Oxidative stress is also believed to participate in the
pathogenesis of HBV-associated HCC. Poungpairoj et
al. (27) reported that plasma protein carbonyl content
was significantly higher and total antioxidant capacity
was significantly lower in HBV-associated HCC patients
when compared to healthy controls. The HBx gene and
its associated protein are important in the pathogenesis of
HBV-related carcinogenesis and in vitro studies have shown
that they induce oxidative stress and mitochondrial DNA
damage in cells (28).
The current study showed that dynamic thiol-disulfide
homeostasis is disturbed and shifts towards the disulfide
side in patients with HBV-associated chronic liver diseases,
which indicates the presence of oxidative stress during the
course of chronic HBV infection. In this context, our results
are consistent with the prior studies in the literature, some
of which were already mentioned above. According to the
results of the current study, serum native and total thiol
concentrations were found to be lower in CHB and cirrhosis
patients when compared to healthy controls. Serum native
and total thiol concentrations were also significantly
lower in cirrhosis patients compared to noncirrhotic CHB
patients, being lowest in patients with decompensated
cirrhosis. These findings indicate that the decrease in serum
native and total thiol concentrations in the course of CHB
is progressive and it is parallel to the stage of the disease and
parenchymal failure.

Our results also showed that mean serum disulfide
concentrations differed significantly among the study
groups, but the situation here was a bit more complex;
although mean serum disulfide concentration was
higher in patients with CHB compared to healthy
controls, the same was not true for cirrhotic patients. We
believe that this is due to the significant decrease in the
serum albumin concentration in patients with cirrhosis.
Albumin thiols constitute a significant amount of the
plasma thiol pool; therefore, besides increased oxidative
stress, decreased serum albumin levels also contribute
to decreased serum total and native thiol concentrations
in cirrhotic patients. In this context, the amount of
thiols to be converted to disulfides would be low in
cirrhotic patients, preventing serum disulfide levels
from increasing further. As can be clearly seen from our
results, although mean serum disulfide concentration
was not different from that of healthy controls in cirrhotic
patients, both disulfide/total thiol and disulfide/native
thiol ratios were significantly higher in cirrhotic patients
when compared to healthy controls, which also supports
our hypothesis .
One of the strengths of the current study is that
it includes a homogeneous group of patients with
chronic liver disease of a uniform etiology, i.e. CHB.
There are many patients with different stages of HBVassociated chronic liver disease and the sample size is
decent for statistical comparisons. On the other hand,
the cross-sectional design of the study constitutes the
major limitation of the study. A prospective study with
serial measurements of serum dynamic thiol-disulfide
homeostasis parameters at different time points during
the course of CHB would better clarify the changes in
the dynamic thiol-disulfide homeostasis during the
course of hepatitis B-related chronic liver diseases.
In conclusion, dynamic thiol-disulfide homeostasis
is disturbed in HBV-related chronic liver diseases. This
implies the possible role of oxidative stress in HBVassociated chronic liver injury. Further studies may
clarify the exact role of oxidative stress and antioxidant
defense mechanisms during the course of HBV-related
chronic liver diseases and may facilitate development of
novel treatment strategies.
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